Back to search results

Investigating [18F]-AraG PET Imaging for Head and Neck Cancer

This study is looking at how a special imaging scan, called an [18F]-AraG PET/CT, can help doctors monitor patients with locally advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) who are receiving standard chemoradiotherapy. You would receive the [18F]-AraG radiotracer on the first and sixteenth day of treatment, along with weekly cisplatin chemotherapy and 70Gy of radiation. Researchers want to see if changes in the PET/CT scans before and during treatment can predict how well the treatment is working. This study is for adults aged 18 and older with LA-HNSCC in specific areas, who are planning to undergo standard chemoradiotherapy. The study aims to enroll 5 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments and tests. It plans to enroll 5 participants.
What's involved
You would receive the [18F]-AraG radiotracer on day 1 and day 16 of treatment. You would also undergo PET/CT scans before treatment, at week 1, and at week 16.
Compensation
Not stated in the trial record.
Follow-up
The study measures outcomes at Week 1 and Week 16, and also compares pre-treatment results with those at Week 16.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07168785

[18F]-AraG PET Imaging in LA HNSCC

Not Yet Recruiting
EARLY_PHASE1Ages 18+InterventionalDiagnostic
Indiana University
~5 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:[18F]-AraG radiotracerChemotherapyRadiotherapy

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
[18F]-AraG PET/CT uptake and infiltrating cytotoxic T-cell expression.
Measured over Week 1 and Week 16
+2 more outcomes measured

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)
Locally Advanced Head and Neck Squamous Cell Carcinoma

Explore related trials

Head and Neck Squamous Cell Carcinoma

Where it's being run

1 sites across 1 states
Indiana1

Study leadership

  • Richard Zellars, MD · PRINCIPAL_INVESTIGATOR · Indiana University Simon Comprehensive Cancer Center

Who to contact

Kathryn I Lauer
[email protected]
(317) 962-8969
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • [18F]-AraG PET/CT uptake and infiltrating cytotoxic T-cell expression.Week 1 and Week 16

    Examining the distribution of \[18F\]-AraG PET SUV metrics and counts of CD3+/CD8+/PD1- and CD3+/CD8+/PD1+ T-cells

  • Pre-treatment [18F]-AraG PET/CT uptake and clinical response.Pre-treatment

    Correlation of pre-treatment \[18F\]-AraG PET/CT metrics (such as SUVmax, mean and uptake volume) and clinical response.

  • Changes between pre-treatment and mid-treatment [18F]-AraG PET/CT uptake and clinical responsePre-treatment and Week 16

    Correlation between percentage changes in PET uptake values (max, mean, and peak) at pre- and mid-CRT and treatment response categories.